Related Experiment Video
Updated: Aug 14, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
[Treatment of dyskinesias with tiapride (author's transl)]
Abstract:
Tiapride was administered to ten patients with late dyskinesias following either prolonged treatment with neuroleptics (nine cases) or Huntington's chorea (one case). The dosage used was 300 mg daily for four weeks, followed by 300 to 600 mg daily during the next four weeks (the basic neuroleptic treatment was continued without modifying the dosage). An objective study on the severity of the dyskinesia demonstrated a significant improvement during the first four weeks, maintained over the following four weeks. Increasing dosage to 900 mg did not modify the results.
Related Concept Videos
Cholinergic Antagonists: Pharmacokinetics
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Alzheimer's Disease: Treatment
Alterations in Muscle Tone lll

